Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 2/20 | 0.59 |
| ▸ | IDO1 | P14902 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 4/20 | 0.43 |
| ▸ | CA2 | P00918 | 4/20 | 0.43 |
| ▸ | CA9 | Q16790 | 3/20 | 0.43 |
| ▸ | CA5A | P35218 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | DAO | P14920 | 2/20 | 0.39 |
| ▸ | ACP1 | P24666 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7127796 | 0.83 | IDO1 (0.47) | KIF11IDO1KMT2ACES2DAO | |
| SCHEMBL4879814 | 0.81 | KIF11 (0.57) | KIF11IDO1CA1CA2CA9 | |
| SCHEMBL31021484 | 0.81 | KIF11 (0.57) | KIF11IDO1CA1CA2CA9 | |
| SCHEMBL496729 | 0.79 | ACP1 (0.50) | KIF11IDO1CA1CA2CES2 | |
| SCHEMBL3130035 | 0.79 | KIF11 (0.89) | KIF11IDO1CA1CA2CA9 | |
| SCHEMBL2376293 | 0.79 | IDO1 (0.44) | KIF11IDO1KMT2ACES2DAO | |
| SCHEMBL2376297 | 0.79 | IDO1 (0.44) | KIF11IDO1KMT2ACES2DAO | |
| SCHEMBL773148 | 0.79 | IDO1 (0.44) | KIF11IDO1KMT2ACES2DAO | |
| SCHEMBL25407852 | 0.75 | KIF11 (0.50) | KIF11IDO1CA1CA2CA9 | |
| SCHEMBL341095 | 0.75 | PPARG (0.41) | KIF11IDO1CES2DAOACP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023134629-A1 | NUCLEAR TRANSPORT REGULATOR AND USE THEREOF | 上海海雁医药科技有限公司 | 2023-07-20 | — | — | WO | disclosed |
| US-7345040-B2 | Reverse-turn mimetics and compositions and methods relating thereto | MYRIAD GENETICS, INC. (US) | 2008-03-18 | — | — | US | disclosed |
| US-20050250780-A1 | Reverse-turn mimetics and compositions and methods relating thereto | MYRIAD GENETICS, INCORPORATED (US) | 2005-11-10 | — | — | US | disclosed |
| WO-2004035587-A1 | REVERSE-TURN MIMETICS AND COMPOSITION AND METHODS RELATING THERETO | MYRIAD GENETICS, INC. (US) | 2004-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250780-A1 | Reverse-turn mimetics and compositions and methods relating thereto | TAC3, NTSR1, SCTR | KIF11 1562/4885IDO1 935/4885CA1 732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.